AI-enhanced breast MRI with a 75% reduced gadolinium dose maintained diagnostic sensitivity comparable to full-dose protocols.
Key Details
- 1Single-center study with 20 female participants having biopsy-proven malignancies or high-risk indications.
- 2Low-dose (0.025 mmol/kg) MRI scans with AI were compared to standard-dose (0.1 mmol/kg) with/without AI.
- 3Diagnostic sensitivity with low-dose + AI was 83.3% (p=1 vs. standard), accuracy was 74.5% vs. 69.5% (standard) and 65.5% (standard+AI).
- 498 lesions detected; 12 were biopsy-proven malignancies; high NPVs (93-94%) across all protocols.
- 5AI-assisted low-dose MRI had the highest PPV (50%) and substantial interreader agreement (kappa 0.65-0.74).
- 6Study was small and lacked long-term outcome data; funded by Bracco.
Why It Matters
Gadolinium retention and cost are growing concerns in breast imaging. This study shows that AI-powered image enhancement could allow safer, lower-dose protocols without compromising cancer detection, marking a significant step for both patient safety and clinical feasibility.
Source
AuntMinnie
Related News
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
AI Technique Unveils Previously Hidden MS Gray Matter Lesions on MRI
Researchers developed an AI-enhanced method to detect previously invisible gray matter lesions in multiple sclerosis using MRI.
•Radiology Business
Majority of Patients Want Disclosure When AI Used in Imaging
A new survey finds that nearly all patients want to be informed when AI is utilized in medical imaging interpretation.